Redsense Medical AB (REDS) - Net Assets
Based on the latest financial reports, Redsense Medical AB (REDS) has net assets worth Skr35.92 Million SEK (≈ $3.87 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr39.81 Million ≈ $4.28 Million USD) and total liabilities (Skr3.89 Million ≈ $418.95K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Redsense Medical AB (REDS) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr35.92 Million |
| % of Total Assets | 90.22% |
| Annual Growth Rate | -14.25% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 45.72 |
Redsense Medical AB - Net Assets Trend (2020–2024)
This chart illustrates how Redsense Medical AB's net assets have evolved over time, based on quarterly financial data. Also explore Redsense Medical AB total assets for the complete picture of this company's asset base.
Annual Net Assets for Redsense Medical AB (2020–2024)
The table below shows the annual net assets of Redsense Medical AB from 2020 to 2024. For live valuation and market cap data, see REDS market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr39.59 Million ≈ $4.26 Million |
+71.40% |
| 2023-12-31 | Skr23.09 Million ≈ $2.49 Million |
-14.93% |
| 2022-12-31 | Skr27.15 Million ≈ $2.92 Million |
-27.59% |
| 2021-12-31 | Skr37.49 Million ≈ $4.03 Million |
-48.78% |
| 2020-12-31 | Skr73.20 Million ≈ $7.88 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Redsense Medical AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 7561949800.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Skr23.78 Million | 60.08% |
| Other Components | Skr15.80 Million | 39.92% |
| Total Equity | Skr39.58 Million | 100.00% |
Redsense Medical AB Competitors by Market Cap
The table below lists competitors of Redsense Medical AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FEEDBACK PLC LS-5
F:GZM0
|
$5.28 Million |
|
Global Power Solutions Corp.
V:PWER
|
$5.28 Million |
|
Tennant Minerals Ltd
AU:TMS
|
$5.28 Million |
|
Chakana Copper Corp
V:PERU
|
$5.28 Million |
|
Envy Technologies Indonesia Tbk PT
JK:ENVY
|
$5.27 Million |
|
Dominion Minerals Ltd
AU:DLM
|
$5.27 Million |
|
Veganz Group AG
F:VEZ
|
$5.26 Million |
|
Kingman Minerals Ltd
V:KGS
|
$5.26 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Redsense Medical AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 23,095,000 to 39,584,000, a change of 16,489,000 (71.4%).
- Net income of 342,000 contributed positively to equity growth.
- New share issuances of 17,230,000 increased equity.
- Other factors decreased equity by 1,083,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr342.00K | +0.86% |
| Share Issuances | Skr17.23 Million | +43.53% |
| Other Changes | Skr-1.08 Million | -2.74% |
| Total Change | Skr- | 71.40% |
Book Value vs Market Value Analysis
This analysis compares Redsense Medical AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.24x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.57x to 1.24x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | Skr5.21 | Skr2.98 | x |
| 2021-12-31 | Skr2.67 | Skr2.98 | x |
| 2022-12-31 | Skr1.93 | Skr2.98 | x |
| 2023-12-31 | Skr1.64 | Skr2.98 | x |
| 2024-12-31 | Skr2.41 | Skr2.98 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Redsense Medical AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.21%
- • Asset Turnover: 0.67x
- • Equity Multiplier: 1.06x
- Recent ROE (0.86%) is above the historical average (-16.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -12.34% | -62.56% | 0.18x | 1.08x | Skr-16.35 Million |
| 2021 | -21.26% | -85.15% | 0.22x | 1.15x | Skr-11.72 Million |
| 2022 | -32.26% | -61.07% | 0.47x | 1.13x | Skr-11.47 Million |
| 2023 | -19.54% | -18.08% | 0.94x | 1.15x | Skr-6.82 Million |
| 2024 | 0.86% | 1.21% | 0.67x | 1.06x | Skr-3.62 Million |
Industry Comparison
This section compares Redsense Medical AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $171,567,428
- Average return on equity (ROE) among peers: -27.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Redsense Medical AB (REDS) | Skr35.92 Million | -12.34% | 0.11x | $5.27 Million |
| Acarix A/S (ACARIX) | $15.12 Million | -127.02% | 0.21x | $33.84 Million |
| Arcoma AB (ARCOMA) | $48.66 Million | 5.27% | 0.68x | $11.55 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $387.11 Million | -0.84% | 0.62x | $61.64 Million |
| BICO Group AB (BICO) | $2.31 Million | 0.00% | 2.47x | $159.82 Million |
| Boule Diagnostics AB (BOUL) | $295.74 Million | 7.87% | 0.93x | $14.38 Million |
| CellaVision AB (CEVI) | $887.58 Million | 17.25% | 0.23x | $311.10 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $26.09 Million | -70.24% | 0.12x | $11.57 Million |
| Chordate Medical Holding AB (CMH) | $25.64 Million | -77.06% | 0.22x | $29.05K |
| C-Rad AB (publ) (CRAD-B) | $29.82 Million | -34.38% | 0.50x | $86.08 Million |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $331.97K |
About Redsense Medical AB
Redsense Medical AB (publ) develops a monitoring system to detect sign of a blood leak using patented fiber optic technology primarily in Europe, Canada, and the United States. The company offers Redsense System, a product that is used for monitoring and alarming in the case of blood leakage during hemodialysis treatment; and Redsense venous sensor patch, a noninvasive patch that consists of an o… Read more